Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Nirmatrelvir / ritonavir - PAXLOVID official renal regimen
Product / population
Nirmatrelvir / ritonavir - PAXLOVID official renal regimen; selected source sections, not a full prescribing monograph.
Renal method
Source prints eGFR in mL/min without a body-surface-area denominator. Indexing is not established; no conversion or relabeling.
Source revision
Prescribing information revised 02/2026.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
PAXLOVID: day 1 differs from days 2-5 in severe impairment
The rechecked RX and official tables retain a day-specific severe-impairment course, with post-HD timing on dialysis days. The same regimen already existed locally.
What to reconcile: Check the treatment day, component doses, renal units and all interactions; a matching mirror is not independent corroboration.
DailyMed / Pfizer Laboratories Div Pfizer Inc · Nirmatrelvir / ritonavir - PAXLOVID official renal regimen; selected source sections, not a full prescribing monograph.
Renal method: Source prints eGFR in mL/min without a body-surface-area denominator. Indexing is not established; no conversion or relabeling. Source date: Prescribing information revised 02/2026. Retrieved: 2026-09-08
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For moderate impairment, printed eGFR >=30 to <60 mL/min, give nirmatrelvir 150 mg with ritonavir 100 mg twice daily for five days. For eGFR <30, including hemodialysis, give 300 mg/100 mg once on day 1, then 150 mg/100 mg once daily on days 2-5. Give after hemodialysis on dialysis days. Mild impairment needs no adjustment. Specify both ingredients and the matching dose pack. The interaction review remains essential; renal reduction does not neutralize ritonavir interactions. The source omits a BSA denominator, so indexing is not silently assigned.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.